A blood test may one day help identify chronic traumatic encephalopathy (CTE) in living people, according to a new study published Thursday in The Journal of the American Medical Association. Researchers did caution that the findings are preliminary and the test is not approved or available for diagnosing CTE.
The study, led by researchers at Boston University and Banner Health, analyzed blood samples from 21 former football players who later donated their brains for examination. Autopsies found CTE in 18 participants; 16 of those cases were advanced, or high-stage, CTE.
Researchers found higher levels of a protein marker called eMTBR-tau in participants with high-stage CTE than in those with low-stage CTE or no CTE. The marker was not elevated in participants whose CTE was at an earlier stage.
CTE is associated with repeated head impacts and can currently only be definitively diagnosed through examination of brain tissue after death.
Researchers said a reliable test during life could eventually help make treatment possible.
“This is a game changer,” said Michael Alosco, a study co-senior author and co-director of clinical research at BU’s CTE Center. He emphasized that the work is still in the discovery phase and requires many more studies.
The study included 12 former professional players, seven former college players and two former high school players. Five participants with CTE also had Alzheimer’s disease; their eMTBR-tau levels were highest. A separate blood marker associated with Alzheimer’s was elevated only in participants who had Alzheimer’s.
A second study by Washington University School of Medicine in St. Louis used different cases and methods, also found elevated eMTBR-tau in people whose CTE was confirmed at autopsy.
Researchers say larger studies are necessary moving forward to confirm that the results are accurate but they hope this could lead to possible treatments of CTE for people who are still alive.